Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas
Determine alone or in combination with chemotherapy or autologous cytokine induced killer cells are effective and safe in the treatment of patients with relapsed and/or refractory solid tumors or B Cell lymphomas.
Solid Tumors|B Cell Lymphoma
DRUG: Decitabine|BIOLOGICAL: cytokine-induced killer cell
Response confirmed by non-investigational CT or MRI, or confirmed by biopsy, within the first 30 days after four-cycle treatment
tumor marker, at least once within 30 days afther completing four-cycle treatment
The purpose of this study is to determine whether lower dose decitabine based therapy is safe and can effectively control tumor progression.